News stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.8730961515855 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Merrimack Pharmaceuticals (NASDAQ:MACK) traded down $0.10 during mid-day trading on Friday, hitting $10.74. 100,754 shares of the stock traded hands, compared to its average volume of 181,500. The stock has a market capitalization of $143.20, a P/E ratio of -1.47 and a beta of 1.72. The company has a quick ratio of 3.35, a current ratio of 3.35 and a debt-to-equity ratio of 0.45. Merrimack Pharmaceuticals has a fifty-two week low of $10.04 and a fifty-two week high of $39.90.
Several brokerages have recently weighed in on MACK. ValuEngine downgraded shares of Merrimack Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Robert W. Baird restated a “hold” rating and issued a $15.00 target price on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Finally, Zacks Investment Research downgraded shares of Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price.html.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.